1. Studying pathophysiology of pre-diabetes and type 2 diabetes at the population level:
Heterogeneity in type 2 diabetes development; relationship between insulin resistance and beta cell dysfunction; role of incretin hormones, obesity, physical activity and diet in type 2 diabetes development.
2. Conducting clinical trials for prevention of type 2 diabetes and cardiovascular disease:
Testing medication and lifestyle interventions in overweight or obese individuals at high risk of developing type 2 diabetes and cardiovascular disease.
1. The PRE-D Trial
Aim: To compare the efficacy of three short-term glucose-lowering interventions (exercise, metformin and dapagliflozin) on glycaemic variability in overweight or obese men and women with elevated diabetes risk (ie, prediabetes, defined as haemoglobin A1c (HbA1c) 39–47 mmol/mol / 5.7%–6.4%). Secondary aims are to investigate the effects of the interventions on body composition and cardiometabolic risk factors.
Collaborators: Marit E. Jørgensen (SDCC), Frederik Persson (SDCC), Mathias Ried-Larsen (Rigshospitalet), Kristian Karstoft (Rigshospitalet). The trial is sponsored by the Novo Nordisk Foundation and Astra Zeneca.
2. The Whitehall II study
Aim: To conduct epidemiological analyses of the relationship of pre-diabetes with lifestyle factors and development of diabetes and cardiovascular disease.
Collaborators: Eric Brunner (UCL, London, UK), Mika Kivimäki (UCL, London, UK), Adam Tabak (Semmelweis University, Hungary), Daniel R. Witte (Aarhus University, Aarhus), Adam Hulman (Aarhus University, Aarhus)